U.S. Food and Drug Administration (FDA) · United States
FDA Unauthorized Medical Device Off-Label Promotion
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.
21 U.S.C. 352(a), (o), (q), (r); 21 CFR 801.4
What is FDA Unauthorized Medical Device Off-Label Promotion?
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks. Apply to US medical device sales aids, HCP and trade marketing, conference materials, websites and social for off-label promotion.
patients, general_audience, general_adults_18plus, health_professionals, customers · Medical Device · healthcare
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-05-10
What does this rule require?
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.
How can marketing teams comply?
Apply to US medical device sales aids, HCP and trade marketing, conference materials, websites and social for off-label promotion.
What is FDA Unauthorized Medical Device Off-Label Promotion?
Medical device promotion must stay within the cleared or approved indications; promoting other uses is misbranding, and restricted-device ads need a brief statement of intended uses and risks.
Who does this rule apply to?
patients, general_audience, general_adults_18plus, health_professionals, customers · Medical Device · healthcare
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.